Results 271 to 280 of about 3,407,318 (341)
Some of the next articles are maybe not open access.
Antiplatelet agents in hemodialysis
Journal of Nephrology, 2016Patients affected by cardiovascular disease (CVD) are treated with antiplatelet agents (AA) and/or anticoagulant drugs, which are fundamental in the management of stroke, coronary atherosclerotic disease, peripheral vascular disease and atrial fibrillation. CVD is the most important cause of death in chronic renal failure (CRF).
Massimiliano Migliori +3 more
openaire +5 more sources
Blood reviews, 2020
Platelets are central to inflammation-related manifestations of cardiovascular diseases (CVD) such as atherosclerosis. Platelet-activating factor (PAF), thrombin, thromboxane A2 (TxA2), and adenosine diphosphate (ADP) are some of the key agonists of ...
R. Lordan, A. Tsoupras, I. Zabetakis
semanticscholar +1 more source
Platelets are central to inflammation-related manifestations of cardiovascular diseases (CVD) such as atherosclerosis. Platelet-activating factor (PAF), thrombin, thromboxane A2 (TxA2), and adenosine diphosphate (ADP) are some of the key agonists of ...
R. Lordan, A. Tsoupras, I. Zabetakis
semanticscholar +1 more source
Hematology, 2009
Abstract The introduction of aspirin as an anti-thrombotic agent some 50 years ago has changed the therapeutic approach in cardiovascular medicine. Since platelets play a key role in the development of arterial thrombosis, antiplatelet drugs serve as a cornerstone in the prevention and the treatment of these conditions.
David, Varon, Galia, Spectre
openaire +2 more sources
Abstract The introduction of aspirin as an anti-thrombotic agent some 50 years ago has changed the therapeutic approach in cardiovascular medicine. Since platelets play a key role in the development of arterial thrombosis, antiplatelet drugs serve as a cornerstone in the prevention and the treatment of these conditions.
David, Varon, Galia, Spectre
openaire +2 more sources
Lab on a Chip, 2020
We have developed a microfluidic system to perfuse whole blood through a flow channel with an upstream stenotic region and a downstream protein capture region.
S. Rahman, V. Hlady
semanticscholar +1 more source
We have developed a microfluidic system to perfuse whole blood through a flow channel with an upstream stenotic region and a downstream protein capture region.
S. Rahman, V. Hlady
semanticscholar +1 more source
Treatment of blunt cerebrovascular injuries: Anticoagulants or antiplatelet agents?
Journal of Trauma and Acute Care Surgery, 2020BACKGROUND Blunt cerebrovascular injury (BCVI) is associated with cerebrovascular accidents (CVA). Early therapy with antiplatelet agents or anticoagulants is recommended. There are limited data comparing the effectiveness of these treatments. The aim of
K. Hanna +8 more
semanticscholar +1 more source
Australian and New Zealand Journal of Medicine, 1998
AbstractAspirin is an established therapy for the management of acute myocardial infarction (AMI) and unstable angina. Secondary prevention with chronic aspirin therapy is also indicated for patients with stable angina.Aspirin inhibits cyclo‐oxygenase‐I, a key enzyme in the biosynthetic pathway leading to the production of thromboxane A2.
H D, White, J K, French, C J, Ellis
openaire +2 more sources
AbstractAspirin is an established therapy for the management of acute myocardial infarction (AMI) and unstable angina. Secondary prevention with chronic aspirin therapy is also indicated for patients with stable angina.Aspirin inhibits cyclo‐oxygenase‐I, a key enzyme in the biosynthetic pathway leading to the production of thromboxane A2.
H D, White, J K, French, C J, Ellis
openaire +2 more sources
Current Opinion in Hematology, 2009
Cardiovascular events are still a major concern despite dual antiplatelet treatment with aspirin and clopidogrel. Moreover, recent developments that improved platelet inhibition were associated with increased bleeding complications, suggesting that personal dose adjustment might be needed.
Galia, Spectre, David, Varon
openaire +2 more sources
Cardiovascular events are still a major concern despite dual antiplatelet treatment with aspirin and clopidogrel. Moreover, recent developments that improved platelet inhibition were associated with increased bleeding complications, suggesting that personal dose adjustment might be needed.
Galia, Spectre, David, Varon
openaire +2 more sources
2018
Antiplatelet agents are commonly used in vascular medicine and cardiology, but also in the pharmacologic management of patients with ischemic stroke. Aspirin alone remains the mainstay of therapy for secondary stroke prevention. Several landmark studies for the optimal duration and dose of antiplatelet therapy in stroke prevention are discussed.
Eelco F. M. Wijdicks, Sarah L. Clark
openaire +2 more sources
Antiplatelet agents are commonly used in vascular medicine and cardiology, but also in the pharmacologic management of patients with ischemic stroke. Aspirin alone remains the mainstay of therapy for secondary stroke prevention. Several landmark studies for the optimal duration and dose of antiplatelet therapy in stroke prevention are discussed.
Eelco F. M. Wijdicks, Sarah L. Clark
openaire +2 more sources
A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents
Journal of clinical pharmacology, 2019Legalization of medical cannabis has occurred in 33 states and the District of Columbia, and recreational use has increased exponentially since 2013. As a result, it is important to understand how cannabis interacts with other drugs and has potential ...
J. Greger +3 more
semanticscholar +1 more source
Oral antiplatelet agents in cardiovascular disease.
VASA. Zeitschrift fur Gefasskrankheiten, 2019Antiplatelet agents significantly reduce mortality and morbidity in ischemic heart disease, cerebrovascular disease and peripheral artery disease (PAD), and are therefore part of guideline-driven daily medical treatment in these patients.
J. Pultar +3 more
semanticscholar +1 more source